Completed

Two Doses of Atevirdine Mesylate and Fixed Doses of Zidovudine (AZT) in HIV+ Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Atevirdine mesylate

+ Zidovudine

Drug
Who is being recruted

Blood-Borne Infections+14

+ Urogenital Diseases

+ Genital Diseases

Over 13 Years
+12 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
See protocol details

Summary

Principal SponsorPharmacia and Upjohn
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Patients are randomized to 1 of 3 treatment groups: U-87201E at 1 of 2 doses or placebo administered every 8 hours. Patients must have taken AZT for at least 3 months prior to randomization.

NCT00002322
Principal SponsorPharmacia and Upjohn
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 13 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeAIDS-Related ComplexHIV Infections

Criteria

6 inclusion criteria required to participate
CD4 count 50 - 350 cells/mm3 within 14 days prior to study entry
Consent of parent, guardian, or person with power of attorney if less than 18 years of age
HIV infection
Ongoing therapy with AZT at 500 - 600 mg total daily dose for at least 3 months prior to study entry
Show More Criteria
6 exclusion criteria prevent from participating
Antiretroviral agents other than AZT within 3 months prior to study entry
Any other investigational drugs
Current diagnosis of malignancy for which systemic therapy will be required during the study
Cytotoxic chemotherapy within 1 month prior to study entry
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 12 locations

Los Angeles County / Health Research Assoc / Drew Med Ctr

Los Angeles, United StatesOpen Los Angeles County / Health Research Assoc / Drew Med Ctr in Google Maps

UCI Med Ctr

Orange, United States

Davies Med Ctr

San Francisco, United States

Infectious Disease Research Institute Inc

Tampa, United States
Completed12 Study Centers